| Identification | Back Directory | [Name]
Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate, compd. with 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate (1:1:1) | [CAS]
1824707-75-6 | [Synonyms]
Azilsartan trimethylethanolamine
Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate, compd. with 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylate (1:1:1) | [Molecular Formula]
C55H53N9O11 | [MOL File]
1824707-75-6.mol | [Molecular Weight]
1016.08 |
| Hazard Information | Back Directory | [Description]
Azilsartan is an angiotensin II receptor antagonist used in the treatment of hypertension, developed by Takeda. It is marketed in tablet form under the trade name Edarbi as the prodrug azilsartan medoxomil (INN, codenamed TAK-491). Azilsartan medoxomil lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. |
|
|